Literature DB >> 19403337

Could natural killer cells compensate for impaired CD4+ T-cell responses to CMV in HIV patients responding to antiretroviral therapy?

Dino Bee Aik Tan1, Sonia Fernandez, Martyn French, Patricia Price.   

Abstract

We evaluated NK cell subsets and functions in previously immunodeficient HIV patients responding to ART. Cytokine receptor mRNA was quantitated in purified CD56+ cells. Data were correlated with CD4+ T-cell counts and IFNgamma responses to CMV. NK cell IFNgamma responses to K562 cells and proportions of CD56lo NK cells were correlated in patients (p < 0.001) and both were lower than in controls (p < 0.001 and p = 0.008, respectively), so all patients had poor NK cell function. Proportions of CD56hi NK cells correlated inversely with current CD4+ T-cell counts (p = 0.006) and perforin expression in CD56hi NK cells was higher in patients than controls (p < 0.05). Hence increased proportions and cytolytic function of CD56hi NK cells may partially compensate for CD4+ T-cell deficiency. NK cell IFNgamma responses correlated inversely with expression of IL-10 and IL-12 receptor mRNA. Expression of these transcripts is reduced by exposure to the cytokines, which may reflect immune activation in immunodeficient patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19403337     DOI: 10.1016/j.clim.2009.03.518

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  2 in total

1.  Which NK cell populations mark the high burden of CMV present in all HIV patients beginning ART in Indonesia?

Authors:  Ibnu A Ariyanto; Riwanti Estiasari; Birry Karim; Ika Praseya Wijaya; Budiman Bela; Amin Soebandrio; Patricia Price; Silvia Lee
Journal:  AIDS Res Ther       Date:  2022-03-15       Impact factor: 2.250

2.  HIV patients stable on ART retain evidence of a high CMV load but changes to Natural Killer cell phenotypes reflect both HIV and CMV.

Authors:  Jacquita S Affandi; Jacinta Montgomery; Silvia Lee; Patricia Price
Journal:  AIDS Res Ther       Date:  2015-12-09       Impact factor: 2.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.